Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.55 |
| ▸ | OXTR | P30559 | 17/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4460233 | 0.99 | HCRTR1 (0.54) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4462733 | 0.88 | HCRTR2 (0.59) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4467106 | 0.84 | HCRTR2 (0.54) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4465521 | 0.84 | HCRTR1 (0.55) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4456695 | 0.83 | HCRTR1 (0.50) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL1037307 | 0.83 | HCRTR2 (0.64) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4457670 | 0.82 | HCRTR2 (0.63) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4457706 | 0.81 | HCRTR1 (0.59) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4457693 | 0.81 | HCRTR1 (0.55) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 | |
| SCHEMBL4466283 | 0.80 | HCRTR1 (0.52) | HCRTR1HCRTR2OXTRAVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258903-A1 | Aminoethane Sulfonamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPSR1 | HCRTR1 2/4885HCRTR2 1/4885OXTR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.